Glucon, Suzuken in glucose monitoring device deal
This article was originally published in Clinica
Executive Summary
Boulder, Colorado-based Glucon has struck a deal with Japanese pharmaceuticals distributor Suzuken concerning the former's glucose monitoring watch (GMW). Under the agreement, Suzuken, which controls 50% of the Japanese diabetes market through its SKK subsidiary, will gain exclusive marketing rights to GMW in that region and be responsible for taking the product through the Japanese regulatory process. In exchange, Suzuken has made an equity investment in Glucon during a recent round of financing, in which other venture capital firms including Giza Venture Capital, Infinity Venture Capital Fund, Reslo Life Sciences and Ascend Technology Ventures also took part.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.